Compare Medpace Holdings Inc (MEDP) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Teradyne, Inc. — how do they compare? Medpace Holdings Inc trades at $533.1 (market cap $15.08B), while Teradyne, Inc. trades at $378.31 (market cap $52.25B). The key difference: Teradyne, Inc. is far larger — about 3.5× Medpace Holdings Inc's market cap, and Teradyne, Inc. pays a 0.16% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TER | |
|---|---|---|
Market Cap | $15.08B | $52.25B |
Sector | Technology | Technology |
52-Week High | $620.59 | $483.84 |
52-Week Low | $308.88 | $90.15 |
Enterprise Value | $14.55B | $52.08B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Teradyne (TER) trades at $334.23, up 3.68% on the day, with strong recent earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but benefits from high profitability margins (net income margin 22.55%) and consistent revenue growth, projected to reach $3.8B in 2026. Analysts maintain a bullish consensus with a $453.60 price target, citing AI infrastructure expansion and recent product launches as key catalysts.
Outlook remains positive given TER's strategic positioning in AI and semiconductor testing, though elevated valuation ratios (P/E 59.81) and technical bearishness pose near-term risks. Investment opportunity hinges on execution in high-growth AI segments, while risks include market volatility and competitive pressures in the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
